Structure-Based Identification of Inhibitors Disrupting the CD2-CD58 Interactions by Tripathi, Neha et al.
RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE
Author(s) - Auteur(s) :
Publication date - Date de publication :
Permanent link - Permalien :
Rights / License - Licence de droit d’auteur :
Bibliothèque Universitaire Moretus Plantin
Institutional Repository - Research Portal
Dépôt Institutionnel - Portail de la Recherche
researchportal.unamur.beUniversity of Namur
Structure-Based Identification of Inhibitors Disrupting the CD2-CD58 Interactions
Tripathi, Neha; Leherte, Laurence; Vercauteren, Daniel; Laurent, Adèle D.
Published in:








Citation for pulished version (HARVARD):
Tripathi, N, Leherte, L, Vercauteren, D & Laurent, AD 2021, 'Structure-Based Identification of Inhibitors
Disrupting the CD2-CD58 Interactions', Journal of computer-aided molecular design, vol. 35, no. 3, pp. 337-353.
https://doi.org/10.1007/s10822-020-00369-z
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 02. Jan. 2022
1 
 
Structure-Based Identification of Inhibitors Disrupting the CD2-CD58 Interactions 
Neha Tripathi,1*Laurence Leherte,2,3 Daniel P. Vercauteren,2 Adèle D. Laurent1* 
1Université de Nantes, CNRS,  CEISAM UMR 6230, F-44000 Nantes, France. 
2Unit of Theoretical and Structural Physical Chemistry, Department of Chemistry, NAmur Research 
Institute for LIfe Sciences (NARILIS), NAmur MEdicine & Drug Innovation Center (NAMEDIC), 
Namur Institute of Structured Matter (NISM), University of Namur, Rue de Bruxelles 61, B-5000 
Namur (Belgium). 
3Laboratory of Structural Biological Chemistry, University of Namur, Rue de Bruxelles 61, B-5000 
Namur (Belgium). 
*Corresponding Authors: Neha Tripathi, Email: Neha.Tripathi@univ-nantes.fr and Adèle D. 
Laurent, Email: Adele.Laurent@univ-nantes.fr   
Abstract 
The immune system has very intricate mechanisms of fighting against the invading 
infections which are accomplished by a sequential event of molecular interactions in the 
body. One of the crucial phenomena in this process is the recognition of T-cells by the 
antigen-presenting cells (APCs), which is initiated by the rapid interaction between both cell 
surface receptors, i.e., CD2 located on T-cells and CD58 located on APCs. Under various 
pathological conditions, which involve undesired immune response, inhibiting the CD2-
CD58 interactions becomes a therapeutically relevant opportunity. Herein we present an 
extensive work to identify novel inhibiting agents of the CD2-CD58 interactions. Classical 
molecular dynamics (MD) simulations of the CD2-CD58 complex highlighted a series of 
crucial CD58 residues responsible for the interactions with CD2. Based on such results, a 
pharmacophore map, complementary to the CD2-binding site of CD58, was created and 
employed for virtual screening of ~300,000 available compounds. On the ~6,000 compounds 
filtered from pharmacophore mapping, ADME screening leads to ~350 molecules. Molecular 
docking was then performed on these molecules, and fifteen compounds emerged with 
significant binding energy (< −50 kcal/mol) for CD58. Finally, short MD simulations were 
performed in triplicate on each complex (i) to provide a microscopic view of the ligand 
binding and (ii) to rule out possibly weak binders of CD58 from the identified hits. At last, 
we suggest eight compounds for in vitro testing that were identified as promising hits to bind 





The immunological response, against pathogenic xenobiotics, graft rejections, or 
autoimmunity to self-antigens,1 is a result of a systematic interplay between various 
immunological cells that include lymphocytes and antigen-presenting cells (APCs). One of 
the essential phenomena in such processes is the interaction between the T-cells and APCs, 
followed by the T-cell activation.2 Their specific adhesion is triggered by the interaction 
between the cell surface receptors, i.e., lymphocyte function-associated antigen 3 (LFA-3), 
also named CD58, and the cluster of differentiation 2 (CD2).3,4 The expression levels of CD2 
and CD58 are altered under certain pathological conditions.5–8 For instance, rheumatoid 
arthritis patients show an increased expression of CD2 and CD58.8  Therefore, targeting CD2 
and/or CD58 in cell signaling has been identified as an important therapeutic strategy in 
various fields such as autoimmune diseases,9 liver transplantation,10 and cancers.11 However, 
differences in their site of expression are observed. The CD2 expression is limited to the 
lymphocytes T-cells and NK cells while CD58 is widely expressed in various APCs, such as 
macrophages.12 Considering its non-hematopoietic expression, targeting CD58 has become 
the primary approach for the treatment of rheumatoid arthritis and psoriasis.13 As such, organ 
transplant rejection has been treated, for instance, with the anti-human CD2 antibodies such 
as BTI-322 antibody14 or MEDI-507 antibody.15  
Considering the wide therapeutic applicability domain, it becomes clear that 
understanding of the recognition mechanism for CD2 and CD58 could lead to the 
identification of new disrupting agents. Both macromolecules are transmembrane proteins 
(Figure 1) and their extracellular domains are involved in the formation of an adhesion 
complex between T-cells and APCs.16 A distance of ca. 135 Å between the two cells has been 
mentioned as optimal to allow additional interactions between other receptors of the cell 
surface for immune-recognition.16 The binding affinity of CD2 for CD58 is very weak (Kd ~ 
1 µM),16 which facilitates the rapid receptor exchange during intercellular recognition. 
Although the complete crystal structure of CD2 and CD58 is not available, the interaction 
domains of the two macromolecules have been experimentally determined (PDB ID: 
1QA9).16,17 The important interaction pairs which help to stabilize the CD2-CD58 complex 
mainly involved salt bridges formed by residues from each partner, i.e., GluA25-LysB43, 
LysA32-GluB95, LysA34-AspB32, GluA37-ArgB48, GluA39-LysB51, GluA42-LysB51, 
ArgA44-AspB31, and GluA78-LysB34 (where chain A is CD58 and chain B is CD2).17,18 
Critical H-bonds between LysA32-AsnB92, AspA33-AsnB92, and AspA84-LysB41 as well 
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as CH∙∙∙π interactions between LysA34 and TyrB86 have also been listed as pivotal for the 
complex formation.17,18 
 
Figure 1. Structural topology and membranous arrangement of CD58 and CD2 (PDB ID: 
1QA9). Critical residues involved in the formation of CD2-CD58 complex are shown in the 
inset as lines, with CD2 in cyan and CD58 in green. H-bonds and CH∙∙∙π interactions are 
shown as dashed lines in yellow and magenta, respectively. APC: Antigen-presenting cells, 
CD: Cytoplasmic domain, TMD: Transmembrane domain, ED: Extracellular domain. 
Strikingly, only a few molecular modeling studies have been reported for the 
structural evaluation of both CD2-CD58 and inhibitor-CD58 complexes. Bayas et al. 
particularly evaluated the force-induced detachment of CD2 and CD58 by employing Steered 
Molecular Dynamics (SMD) simulations.18 The authors identified the critical salt bridges for 
the formation of the CD2-CD58 complex,17,18 which correlates well with the reported site-
directed mutagenesis experiments. Wang et al. investigated the effect of CD2-glycosylation 
on the CD2-CD58 complex formation19 suggesting that the binding of CD2 to CD58 is 
governed by the relative position of three loops located at the CD58 binding interface 
(quantitatively measured as the distance between three atoms, i.e., LysB41-Cα, LysB51-Cα, 
and GlyB90-Cα in CD2) which in turn is regulated by the glycosylation of AsnB65 (located 
on the opposite interface). The absence of AsnB65 glycosylation results in an increased 
distance between these three Cα atoms and therefore, the failure of CD2-CD58 complexation. 
Considering the tendency to form aggregates and poor solubility of non-glycosylated 
immunoglobulins, Sun et al. proposed apolar-to-polar substitutions in CD58, as a 
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compensation for the glycosylation without a loss in function for the residues not involved in 
CD2 binding.20 Additionally, Lys61Glu, Phe63Leu, and Thr67Ala mutations were 
incorporated in CD2 to impart structural stability in absence of glycosylation.17,20 The 
available crystal structure for CD2-CD58 complex (PDB ID: 1QA9)17 thus represents the 
non-glycosylated CD2 and CD58 mutants. Within the drug design framework, several 
conformationally constrained peptides were already designed to mimic the two CD2 β-
strands enriched in charged residues that are interacting with CD58 to avoid the interaction 
between both partners.21–25 Their efficiency in inhibiting the CD2-CD58 interaction was 
evaluated with cell adhesion assays. To understand the atomic-level details of the inhibitor 
binding with CD58, three known cyclic ligands21–25 (P6, P7, and RTD-c) mimicking the C 
and F β-sheets of CD2 were already investigated by our groups, using molecular docking and 
molecular dynamics (MD) simulations.26 It was shown that the pivotal residues for the 
interaction between CD58 and such cyclic inhibitors include AspB32, TyrB86, and AspB87 
(from the cyclic inhibitors).26  
To our knowledge, all efforts made for inhibiting CD2-CD58 interactions were 
addressed by designing cyclic peptides mimicking the C and F β-sheets of CD2, while no 
work has been reported yet on the identification of non-cyclic compounds. The present work 
aims at fulfilling such a gap starting from the available X-ray structures to perform classical 
MD simulations and revealing key residues contributing to CD2-CD58 stabilization. This 
step was followed by a structure-based pharmacophore map generation and virtual screening 
of 227,228 compounds, available from various libraries. After a filtering step using drug-
likeness and pharmacokinetic parameters, 343 compounds were identified with satisfactory 
parameters. A systematic molecular docking was carried out on these compounds, followed 
by 50 ns MD simulations in triplicate to, at last, clearly identify eight promising compounds 
disrupting the CD2-CD58 interactions according to our in silico strategy.  
Computational Methodology 
Molecular Dynamics Simulations 
The crystallographic structure of the CD2-CD58 complex is available in the 
RCSB/Protein Data Bank (PDB ID: 1QA9).17 This structure is a dimer of the CD2-CD58 
complex, which contains the adhesion domain from the extracellular segment of CD2 and 
CD58. The utilized structure is with apolar-to-polar mutations at sites far from the CD2 
interacting interface to facilitate the computational experiments with non-glycosylated forms 
and to maintain the functional state of the CD2-CD58 complex. We have used only one dimer 
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(CD2-CD58 complex) for the subsequent molecular modeling studies. To evaluate the 
dynamics of the complex and to identify the residues which are critical for the complex 
stabilization, classical MD simulations were performed using the AMBER18 package27 
starting from the X-ray structure. Moreover, MD simulations were also carried out on the 
isolated apo forms using the extracted monomers from the CD2-CD58 complex (PDB ID: 
1QA9).17 The various systems were prepared with the help of Amber tools27 (see 
Supplementary Information (SI) for details, Table S1). The ionization states of various amino 
acids, predicted using the protassign utility (using PROPKA,28 pH 7.0 ± 2.0) (discussed in 
the molecular docking section), were kept during the MD simulations (Figure S1). To 
maintain uniformity with the previous study by our group,26 the ligands (obtained after virtual 
screening) and proteins were treated using the General Amber Force Field (GAFF)29 and the 
Amber ff99SB force field,30 respectively. Additionally, for comparative analysis, GAFF2 
(ref. 31) and FF14SB force field32 were employed for ligands and protein, respectively, for 
CD2-CD58 complex and some of the selected hits (discussed later). The terminal residues are 
located far from the interface of the CD2-CD58 complex and the expected ligand-binding site 
(Figure S2). The C- and the N-terminal of proteins were deprotonated and fully protonated, 
respectively. The generated assemblies were submitted to minimization, gradual heating 
(from 0 to 300 K, under the NVT), and equilibration (1 ns under the NPT, at 310 K and 1 atm 
pressure). Finally, production runs (500 ns under NPT) were performed for all systems, i.e., 
the CD2-CD58 complex, and the CD2 and CD58 apo forms (pressure relaxation time = 2.0 
ps, time step = 2 fs, and cut-off distance for non-bonded interactions = 12 Å). All simulations 
were run in triplicate to evaluate the reproducibility of the results. The MD results were then 
analyzed with the help of the ptraj module33 of the Amber27 and Visual Molecular Dynamics 
software (VMD).34 The replicate simulations were submitted to a combined clustering 
analysis (hierarchical agglomerative (bottom-up) approach, implemented in ptraj),33 in which 
the root mean square deviation (RMSD) was employed as the clustering parameter. The 
binding energy (∆Gbind) values were calculated using the Molecular Mechanics-Generalized 
Born Surface Area (MM/GBSA)  method.35 The complexes between CD58 and hits obtained 
after virtual screening were also submitted to MD simulations using the same protocol but 
with a 50 ns production run (top three binding conformations for each ligand, termed as 





To identify the crucial structural features and the residues responsible for the 
formation of the heterodimeric complex between CD2 and CD58, pharmacophore mapping 
was employed using the crystal structure of the CD2-CD58 complex. The surface area 
between the two macromolecules is ca. 1,200 Å2, with roughly equal contribution from both 
the partners.17 Arulanandam et al. reports a surface area of 770 Å2 for the CD58-binding 
site.36 To make this step efficient, pharmacophoric feature selection was guided by the 
binding energy and per-residue decomposition energy calculations performed following the 
MD simulations. The CD58 residues which contributed to the binding with CD2 by an energy 
equivalent to or less than –1.0 kcal/mol (in all the three replicate runs) and participated in 
close interaction with CD2 surface were considered to be important for the development of 
the pharmacophore map. Selected residues are LysA32, AspA33, ArgA44, and PheA46. The 
pharmacophore model was then defined based on the selected nine potential pharmacophore 
features (discussed later) complementary to the CD2-binding site using the Phase module37,38 
of the Schrödinger software package.39  
The 3D structures of the 227,228 compounds, collected from various small molecular 
libraries (Table S2) were prepared using the LigPrep module of Schrödinger.40,41 In such a 
process, their ionization states were generated using Epik ionizer42–44 (at pH 7.0 ± 2.0). 
Subsequently, the prepared ligands were submitted for the prediction of conformers using the 
ConfGen utility of Schrödinger,45,46 the maximum number of conformers to be generated 
being kept to 10. For the pharmacophore hypothesis based screening, functionally similar 
features, i.e., (i) hydrophobic groups and aromatic rings, (ii) H-bond donating (HBD) and 
positive functional groups, were treated equivalently. From the 227,228 compounds 
considered in the ligand dataset, 5,882 unique molecules simultaneously exhibited at least six 
out of the selected nine features, defined by the pharmacophore model, and were then further 
taken for the next step of virtual screening. 
Property-Based Filtering to Identify Drug like Compounds 
The molecular descriptors of the small molecules can be correlated to their 
physicochemical properties, which in turn govern their pharmacokinetic behavior. 
Considering this, property-based filtering was employed regarding the molecules selected 
after the pharmacophore map-based screening. In the first step, the Drug Likeness Tool 
(DruLiTo)47 was utilized. The filtered compounds were submitted to the calculation of 
various molecular descriptors and subsequent filtering based on various drug-likeness rules 
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including the Lipinski’s rule,48 Ghose filter,49 Veber rule,50 MDDR like rule,51 BBB 
likeness,52 unweighted quantitative estimation of drug likeness rule (uwQED), and weighted 
QED (wQED).53 Compounds with uwQED > 0.4 were taken for the next step of screening, in 
which the QikProp module54 of Schrödinger software was employed to calculate the 
pharmaceutically important properties of small molecules (Table S3). The selection criteria 
for the next step of virtual screening, i.e., molecular docking, was set as #metabol <5, percent 
absorption >80%, and QpLogHERG  > −5. 
Molecular Docking Based Virtual Screening 
In a third step, a systematic molecular docking based screening protocol was adopted. 
To begin with, the pre-processing of the CD58 macromolecular structure (last frame from the 
complex after MD simulations, which belongs to the most populated cluster in the MD 
simulation trajectory, as discussed later) was performed, using the Protein Preparation 
Wizard module40 of Schrödinger,55 in which missing hydrogens were added, water molecules 
beyond 5 Å were removed, and the correct bond orders were assigned. This step was adopted 
to parameterize the atoms for molecular docking. The protonation state and orientation of the 
side chain functional groups of amino acids were predicted with the help of the protassign 
utility (using PROPKA,28 pH 7.0 ± 2.0), which assigns the same pKa values as predicted by 
the PDB2PQR server (http://server.poissonboltzmann.org/pdb2pqr).56 This was followed by a 
restrained minimization (cut-off RMSD = 0.3 Å) with the impref utility. The ligands obtained 
after the property-based screening were submitted to a structure preparation using the 
LigPrep module of Schrödinger.40,41 In such a process, their protonation states were generated 
using Epik ionizer 42–44 (at pH 7.0 ± 2.0).  
The interaction site for the small molecules was defined at the centroid of the above-
mentioned residues, as identified from the MM/GBSA ∆Gbind and per-residue decomposition 
energy calculations (grid center: 6.42, 54.59, 56.35; inner box: 10 Å3, outer box: 20 Å3) using 
the Receptor Grid Generation module of Schrödinger. Glide of Schrödinger57–60 was 
employed for the molecular docking based virtual screening performed in three sequential 
steps, i.e., (i) high-throughput virtual screening (HTVS) (one pose per ligand), (ii) Standard 
Precision (SP) mode docking (20 poses per ligand), (iii) eXtra Precision (XP) mode docking 
(20 poses per ligand), and (iv) Induced Fit Docking (IFD) (20 poses per ligand).61–63 All 
parameters were set to default values and the OPLS_2005 force field64 was used for the 
molecular docking stage. Prime MM/GBSA calculations for the binding energy were 
8 
 
performed after the SP mode docking and the molecules with ∆Gbind values < −35 kcal/mol 
were submitted to the XP mode semi-flexible molecular docking, for which the selection 
criteria was set to Prime MM/GBSA ∆Gbind values < −40 kcal/mol. The pose filtering was 
guided by the presence of the crucial interactions with CD58 and reproducibility of the 
docked conformations. This resulted in the selection of fifteen molecules for the next step of 
virtual screening. The selected fifteen molecules, which will be referred to hereafter as 
compounds 1 to 15, were submitted to flexible molecular docking (IFD) (grid at the centroid 
of LysA32, AspA33, ArgA44, and PheA46; inner box: 10 Å3, outer box: 30 Å3; distance cut-
off: 5 Å; molecular docking in SP mode), for which the Prime MM/GBSA ∆Gbind value cut-
off was set to < −50 kcal/mol.  
Results and Discussion  
Key residues stabilizing CD2-CD58 interactions  
The crystallographic structure for apo-CD2, apo-CD58, and the CD2-CD58 complex 
are available in RCSB/PDB (Table S4). Interestingly, the complexed forms of CD2 and 
CD58 have a few mutated residues as compared to the apo-forms of CD2 and CD58 (Figure 
S3), to impart structural stability in the absence of glycosylation.17,20 In the CD2-CD58 
system, the three residue mutations, incorporated in CD2 are Lys61Glu, Phe63Leu, and 
Thr67Ala, whereas the incorporated mutations in CD58 are Val21Gln, Thr63Ser, Met65Ser, 
and Leu93Gly. Figure 2 depicts the structural superimposition of apo-CD58 (in magenta) and 
CD2-bound CD58 (in cyan) which helps to identify the residues exhibiting a conformational 
change between the unbound and bound CD58. Looking at the binding CD2-CD58 interface, 
several residues such as Phe1 (Ser1 in apo-CD58), Asn20, ValA21 (GlnA21 in apo-CD58), 
GluA25, GluA39, AsnA40, ArgA44, GluA76, GluA78, AsnA81, and AspA84 change their 
conformations in the presence/absence of CD2. Among them, GluA25, GluA39, and GluA78 
are known to be involved in the formation of salt bridges in the CD2-CD58 system (Figure 
1).17,18  
The resolution of the available CD2-CD58 crystal structure is 3.2 Å (Table S4). There 
are 208 close contacts (with clash overlap > 0.4 Å) in the complete structure, with 76 
intramolecular close contacts (43 in CD58 and 33 in CD2) and 9 intermolecular close 
contacts, within the dimer used for the molecular modeling studies in this work (Table S5).17 
Therefore, a 500 ns MD simulation (in triplicate) was performed starting from the 
crystallographic structure of the CD2-CD58 complex (PDB ID: 1QA9) to resolve the close 
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contacts in the structure and to evaluate the key features of the CD2-CD58 binding. In our 
previous work,26 the cyclic peptides were observed to shift from the initial and expected site 
of binding in CD58. Considering this, an additional purpose of performing MD simulations 
of the CD2-CD58 complex was to identify the most stable intermolecular interaction during 
the simulations and select the residues with a higher contribution in terms of binding energy 
in the formation of the complex. 
 
Figure 2. Structural superimposition of apo-CD58 (magenta, PDB ID: 1CCZ) and CD2-
bound CD58 (green, PDB ID: 1QA9). The residues with differing conformations are shown 
as sticks. The CD58 residues which are mutated in the CD2-CD58 complex are labeled in 
magenta and cyan, for the apo-CD58 and CD2-bound CD58.  
Combined clustering analysis for the CD2-CD58 complex (Figure S4A) shows that 
the results for two replicates (named Run1 and Run2) are highly similar, as indicated by the 
presence of more than 90% of the frames in one cluster (C#0). The third replicate (Run3) 
exhibited a distribution of structures spanned over two clusters (48.14% of C#0 and 51.5% of 
C#1) (Figure S4A). To identify the component responsible for non-reproducible results 
during the MD simulations, an additional clustering analysis was performed based on CD2 
and CD58, separately. CD2 exhibits a distribution of coordinates over a single cluster for all 
the replicated simulations (Figure S4B) while CD58 exhibited a wider distribution of 
structure over multiple clusters (Figure S4C). The RMSD value (Table S6) between the 
centroid frame of clusters C#0 and C#1 (in the combined cluster analysis of three replicate 
simulations) was 1.74 Å (calculated for CD2 and CD58) when aligned on the whole CD2-
CD58 complex. On the other hand, the alignment on CD58 or CD2 showed a RMSD value of 
1.15 Å and 1.88 Å (Table S6), respectively.  The system stability analysis ensured that the 
CD2-CD58 complex was well equilibrated during the simulation period for all replicates 
(Figure S5). The whole system RMSD for the complex was less than 3.5 Å over the 
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simulation period, as compared to the initial structure. The analysis of the backbone RMSD 
for CD2 and CD58 in the complex showed an RMSD below 2 Å, indicating that the 
fluctuations are mainly arising due to side-chain flexibility of the surface residues. The 
insignificant difference observed in the radius of gyration of the complexes ensures a stable 
complex formation during the MD. The distance between the center of mass (COM) for the 
CD2 and CD58 in the complex was nearly constant in all three replicate simulations, 
indicating a stable complex formation. It is observed that the absence of glycosylation does 
not affect the formation of the CD2-CD58 complex, when the apolar-to-polar mutations,20 are 
incorporated in the macromolecules according to the in vitro experiments. The computed B-
factor and the atomic fluctuations show that CD2 exhibited much lower dynamics as 
compared to CD58, which is in agreement with the experimental B-factors. To understand the 
per-residue fluctuation pattern of the two macromolecules, the apo-CD2 and apo-CD58 
structures were also submitted to MD for 500 ns, in triplicate. The reproducibility and system 
stability analyses (Figure S6) confirmed that the three simulations behaved similarly for apo-
CD2 and apo-CD58. A comparative analysis of atomic fluctuation (Figure S7) in apo-CD2, 
apo-CD58, and CD2-CD58 complex showed that CD2 exhibits a similar atomic fluctuation. 
On the other hand, CD58 in the complex exhibits a much higher fluctuation as compared to 
apo-CD58 (Figure S7A-S7C). The analysis of the location for the residues with atomic 
fluctuation > 3 Å (Figure S7D) showed that most of these residues are located at the protein 
surface (Figure S7E), and thus have more flexibility as they are exposed to the solvent in the 
simulation.    
After ensuring that the MD simulation trajectories for the CD2-CD58 complex have 
reached stability along the simulation run, we proceeded to an in-depth analysis of the 
interactions between the two partners. The binding energy analysis performed for each of the 
20 ns indicates a highly fluctuating pattern (Figure S8). The MM/GBSA ∆Gbind values for 
Run1 and Run2 were similar to each other but not with Run3. However, the ∆Gbind values 
between 400 and 500 ns were observed to be stable for the three replicates. The average 
∆Gbind for the CD2-CD58 complexation over the last 100 ns for Run1, Run2, and Run3 are –
22, –22, and –42 kcal/mol, respectively, whereas that for the most populated clusters (Figure 
S9) identified during the individual clustering analysis (based on interfacial residues from 
CD2 and CD58) was calculated to be –23, –18, –44 kcal/mol, for Run1, Run2, and Run3, 
respectively. The residue-wise decomposition energy values were analyzed to identify the 
pivotal residues with a reproducible significant contribution in the CD2-CD58 complex. This 
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was achieved (i) through the occupancy analysis (frequency of residue occurrence during the 
various calculations) for the various residues in three simulations (Figure 3A), and (ii) by 
evaluating the averaged per residue decomposition energy values for the most populated 
cluster (C#0 for Run1, Run2, and Run3 in Figure S9).  
Regarding the occupancy analysis, the decomposition energy for each residue was 
averaged over every 20 ns (counted as one calculation). The residues which exhibited binding 
energy < 1.0 kcal/mol (with CD2) for more than 30% of the calculations were considered as 
important for the CD2-CD58 complex formation. In this process, seven CD58 residues 
possess a higher occupancy in all three replicate simulations: LysA32, AspA33, GluA37, 
GluA39, ArgA44, PheA46, and ProA80 (Figure 3A). Among them, two have never been 
reported as playing a key role in the CD2-CD58 interactions, i.e., PheA46 and ProA80. Based 
on such analysis, GluA25, LysA29, GluA76, ThrA83, and AspA84, showed a significant 
contribution to the CD2-CD58 complex formation during Run3, but not in Run1 and Run2, 
and hence could be responsible for the observed lower binding energy of CD2 for CD58 
during Run3. The per-residue decomposition energy analysis showed that the contribution 
from these residues (except for GluA37 and GluA39) was considerably more stable 
throughout the simulations for the three replicates (Figure S10).  
Similarly, seven CD2 residues that were involved in the CD58 interaction were 
identified from the occupancy analysis for the three replicates (Figure S11): AspB31, 
AspB32, ArgB48, TyrB86, GlyB90, LysB91, and AsnB92. Most of these CD2 residues were 
involved in salt bridges or H-bonds in the crystallographic structure while GlyB90 backbone 
(H-bond with LysA34 of CD58) and AsnB92 side chain (H-bond with AspA32 of CD58) 
were detected as the most stable interactions via Steered MD.18 Employing the second 
method, i.e., the average per residue decomposition energy analysis for the most populated 
clusters for the three replicates resulted into the identification of LysA32, GluA37, GluA39, 
ArgA44, PheA46, AspB31, AspB32, TyrB86, GlyB90, LysB91, and AsnB92 (Figure S12) as 
the important residues for the complex formation, which are overlapping with the ones 
identified from the first method in this work. To understand the observed differences between 
Run3 and the other two replicates, we also performed a clustering of the simulation 
trajectories based on the all-atom RMSD of the interfacial residues selected after 
decomposition energy analysis. Out of the simulations, Run1 and Run2 show similar results 
during the combined clustering analysis, whereas Run3 shows a significant difference in the 
configuration of the interfacial residue from CD2 over the last 250 ns, where the CD2 
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conformation spanned over two clusters (Figure S13). Such a distribution was not observed in 
Run1 and Run2. In the combined clustering, the frames extracted from Run3, equally span 
over C#0 (47%) and C#1 (53 %) for CD2, whereas for Run1 and Run2, the C#0 is the 
majorly populated cluster (81% and 100%, respectively) (Figure S13). It is very likely the 
origin of the significant differences in terms of binding energy. 
 
Figure 3. Identified key residues in the CD2-CD58 interaction (A) Occupancy analysis for 
the CD58 residues contributing to the ∆Gbind value for CD2 by more than −1.00 kcal/mol in 
the three simulations (Run1, Run2, and Run3); (B) selected CD58 residues (shown as sticks) 
and the important residues from CD2 (shown as lines); and (C) decomposition energy for the 
selected CD58 residues over the period of 500 ns MD simulation for replicate Run2. 
The topographical positions for the identified residues are shown (as lines) in Figure 
3B. It can be clearly stated that although ProA80 from CD58 was identified to have a 
significant contribution to the decomposition energy (Figure 3A), the selected CD2 residues 
were not involved in direct interaction with ProA80 (Figure 3B). The observed low energy is 
due to the intramolecular interactions of ProA80 within CD58 and was therefore not 
considered for the analysis. The per-residue decomposition energy for the CD58 residues 
identified from the occupancy analysis, in the three replicate simulations shows that Run1 
and Run3 exhibited a higher degree of fluctuation in the energy contribution of GluA37 and 
GluA39 (Figure S10). On the other hand, Run2 exhibited a stable energy contribution for all 
six residues after 300 ns of the simulation period (Figure 3C).  Therefore, the observed order 
in the binding affinity during three simulation replicates is Run3 > Run1 > Run2. Considering 
the variation in the energy contribution between the replicate runs, both residues were not 
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considered later for the pharmacophore development. Therefore, solely four CD58 residues 
were taken into account for the development of the pharmacophore map, i.e., LysA32, 
AspA33, ArgA44, and PheA46.  
Pharmacophore Mapping and Virtual Screening 
As discussed in the previous sections, only a part of the entire interface in the CD2-
CD58 complex is responsible for the binding of the two macromolecules (Figure 3B). 
Therefore, the pharmacophore map generation was performed at the centroid of the key 
CD58 residues LysA32, AspA33, ArgA44, and PheA46 (Figure 4A). A total of fifteen 
pharmacophoric features were detected: four hydrogen bond acceptors (HBA, noted by Ax), 
five hydrogen bond donors (HBD, noted by Dx), two hydrophobic functional groups (noted 
by Hx), one negatively charged group (noted by Nx), two positively charged groups (indicated 
by Px) and one aromatic feature (indicated by Rx). From these fifteen features, nine of them 
were selected regarding their relative positions on the CD58 surface, as well as their relative 
position to the others. The selected features include two HBA (A1 and A4), three HBD (D6, 
D7, and D9), two hydrophobic groups (H10 and H11), one negative functional group (N12), and 
one aromatic group (R15) (Figure 4B). The selection was optimized to keep the generated 
pharmacophore map compact and include the non-overlapping features only. From these 
features, A1 and H11 corresponded to LysA32, D6, and N12, to AspA33, D7, and H10, to the 
side chain guanidine group of ArgA44, and A4, D9, and R15 belonged to PheA46 (Figure 4A). 
Since the ligands interacting at a particular binding site are assumed to exhibit 
complementary features to the HBD, HBA, and ionic functional groups, the generated map 
was manually modified to reverse the interacting nature of these groups. The finally 
generated hypothesis is shown in Figure 4B, in which the HBAs are replaced by HBDs, 
HBDs by HBAs, and negative functional groups are exchanged with positive ones. The 
generated complementary pharmacophore hypothesis was employed for the screening of the 
compound library (Table S2).  
To identify new CD58-binding agents that might specifically inhibit the CD2-CD58 
interactions, a systematic virtual screening protocol (Figure S14) was adopted (see 
computational methodology section for details). In this process, the first step was the 
pharmacophore map-based screening to identify the molecules which exhibited 
complementary features to that of the CD2-binding site of CD58. We utilized the last 
structure from the MD simulations, which belonged to the most populated cluster (Figure 
S4), and exhibited an RMSD of 1.43 Å with the centroid of this cluster (Figure S15). There 
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were no significant differences at the CD2 interacting interface, especially regarding the 
residues considered as important for virtual screening protocol. The presence of six features 
out of the selected nine features was considered as the criterion for the pharmacophore-based 
filtering. A total of 5,882 molecules out of 227,228 compounds exhibited a minimum of the 
selected six features. The structural superimposition of the top twenty molecules (based on 
the PhaseScreen score) with the generated pharmacophore map is presented in Figure S16. 
Features H11, Dc1, Ac6, and R15 were present in almost all the selected compounds. An 
interesting categorization of molecules was observed among the filtered molecules, which (i) 
either exhibited H11, Dc1, Ac6, R15, Dc4, and Ac9 (green in Figure 4D) (ii) or exhibited H11, Dc1, 
Ac6, R15, H10, and Ac7 (magenta in Figure 4D).  
 
Figure 4. Pharmacophore map-based virtual screening to identify the CD58 binding moieties. 
(A) Identified structural features, which are responsible for binding CD2 (cyan), at the CD58 
surface (green). Residues considered for the development of the pharmacophoric hypothesis 
shown as sticks. (B) The pharmacophoric hypothesis, which was considered for virtual 
screening, features complementarity to the CD2-binding site in CD58. (C) Two molecules (in 
magenta and green) aligned to the generated pharmacophore to represent the molecular 
features that are majorly present in the selected compounds. 
The filtered 5,882 molecules were then submitted for the prediction of their 
physicochemical characteristics and thus their pharmacokinetic properties. Such a principle 
was the basis of many drug-likeness evaluation tools, which evaluate the suitability of a 
particular compound according to reported filters. One interesting tool is DruLiTo47 which 
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along with the several well-known drug-likeness filters also incorporates the quantitative 
estimation of drug-likeness in the filtering process (see SI for the property-based filtering 
details, Table S7, Figure S17-S18). After calculating the molecular properties of the various 
molecules, 343 unique compounds were identified to be suitable as plausible drug candidates 
and were taken for the next step of virtual screening, i.e., molecular docking at the CD2-
binding site in CD58. 
Molecular Recognition of the Identified Hits after Molecular Docking 
  To evaluate the molecular recognition potential of the selected compounds for CD58, 
molecular docking studies were performed with an increasing degree of precision. Out of the 
343 molecules submitted to the HTVS procedure, 269 exhibited a docking score < −2, which 
were taken for semi-flexible docking. During the Standard Precision (SP) mode docking, 41 
molecules exhibited a reproducible binding conformation and a Prime MM/GBSA ∆Gbind 
values < −35 kcal/mol, which were then subjected to the eXtra Precision (XP) mode. From 
these 41 molecules, fifteen exhibited a Prime MM/GBSA ∆Gbind values < −50 kcal/mol. The 
2D structures of these fifteen compounds are presented in Figure S19. Considering the non-
flexibility of the protein side chains in SP and XP mode, the filtered fifteen molecules were 
submitted to the Induced Fit Docking (IFD) (with SP mode) to take the amino acid side chain 
flexibility into account.  
 Molecular docking showed that the fifteen molecules occupied the CD2-binding 
interface in a wide range of orientation (Figure S20). To accommodate the docked molecules, 
the loops present on the CD2-binding surface of CD58 were considered to be flexible (green 
in Figure S20). The results for the docking using IFD (for the pose with the lowest value of 
Prime-MM/GBSA ∆Gbind) are presented in Table 1. The 3D interaction diagrams for 
compounds 1-15 are shown in Figure 5. 2D-interaction diagrams are also presented in 
Figures S21-S22. The top-scoring compound 1 exhibited a Prime-MM/GBSA ∆Gbind of −65 
kcal/mol and a glide gscore of −7.91. The molecular recognition interactions which stabilized 
the complex of compound 1 with CD58 include H-bond interactions with LysA34, SerA47, 
SerA48, and NH‧‧‧π interactions with LysA30. Other residues which participated in the 
accommodation of compound 1 in the CD2-binding site are LysA32, AspA33, ValA35, 
PheA46, PheA49, SerA70, AspA71, and TyrA75. For most of the selected molecules, 
LysA30, LysA32, AspA33, LysA34, and SerA47 from CD58 participated in H-bonds/salt 
bridges/CH···p/ NH···p interactions. The selected compounds were rich in H-bond accepting 
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groups (Figure S19), which facilitated their accommodation and interactions at the CD58 
surface.  











Residues within 4 Å 
1 −7.91 −65 LysA30, LysA34, 
SerA47, SerA48 
LysA32, AspA33, ValA35, PheA46, 
PheA49, SerA70, AspA71, TyrA75 
2 −5.22 −61 AspA33, SerA47, 
SerA48, PheA49 
LysA30, LysA34, ValA35, ArgA44, 
AlaA45, PheA46, LysA50 
3 −6.61 −59 AspA33, SerA47, 
SerA48, LysA50 
LysA30, LysA34, ValA35, ArgA44, 
AlaA45, PheA46, PheA49, ArgA52, 
SerA70, AspA71  
4 −5.97 −58 LysA30, SerA47, 
SerA48, ArgA52, 
AspA71 
AspA33, LysA34, ValA35, PheA46, 
PheA49, ThrA68, SerA70  
5 −4.72 −56 AlaA45, PheA46, 
LysA50, AsnA51 
LysA32, AspA33, LysA34, PheA43, 
ArgA44, SerA47, ValA53 
6 −5.31 −59 AspA33, 
LysA34, SerA47 
LysA30, LysA32, ValA35, GluA37, 
ArgA44, AlaA45, PheA46, SerA48, 
PheA49, LysA50 
7 −5.20 −53 LysA30, LysA32, 
AspA33, 
LysA34, SerA47 
GlnA31, ValA35, PheA46, SerA48, 
PheA49, TyrA75 
8 −6.58 −54 LysA30, SerA47, 
SerA48, AspA71 
AspA33, LysA34, ValA35, ArgA44, 
PheA46, PheA49, ArgA52, SerA70 
9 −5.40 −54 AspA33, SerA47, 
SerA48 
LysA30, ValA35, PheA46, PheA49, 
ArgA52, ThrA68, SerA70, AspA71 
10 −5.38 −51 LysA34, PheA46, 
SerA47 
LysA30, AspA33, ValA35, GluA37, 
ArgA44, SerA48, PheA49 
11 −4.98 −57 LysA34, AlaA45, 
SerA47, LysA50 
AspA33, PheA43, ArgA44, PheA46, 
AsnA51, ValA53 
12 −4.52 −51 AspA33, SerA47, 
LysA50 
LysA29, LysA32, LysA34, PheA43, 
ArgA44, AlaA45, PheA46, AsnA51, 
ValA53 
13 −4.90 −50 LysA34, AlaA45, 
LysA50 
AspA33, PheA43, ArgA44, PheA46, 
SerA47, AsnA51, ValA53 
14 −4.78 −54 AlaA45, LysA50 LysA34, GluA37, GluA39, AsnA40, 
PheA43, ArgA44, PheA46, SerA47, 
AsnA51, ValA53 
15 −3.97 −54 LysA34, LysA50 LysA32, AspA33, PheA43, ArgA44, 





Figure 5. 3D interaction diagrams for the compounds 1-15 after the Induced Fit Docking 
(IFD) with CD58. Hydrogen bonds are noted as yellow dotted lines, π···π interactions as blue 





MD Simulations of the Promising Hits 
 To simulate the binding of the selected compounds under physiological conditions, 
we performed MD simulations of the fifteen compounds selected after the IFD procedure, 
with a Prime-MM/GBSA ∆Gbind lower than −50 kcal/mol. The structural overlap of the top 
three conformations (after molecular docking) for each molecule is presented in Figure S23 
and their respective binding affinities, calculated from Prime-MM/GBSA are indicated in 
Table S8.  To identify the relevance of the binding conformation, the top three poses (in 
terms of binding affinity) (Figure S23) were considered for the MD simulations (50 ns each).  
The system stability analysis was performed by the evaluation of the protein backbone 
and ligand RMSD over the simulation periods. As observed in Figure S24, the CD58 
backbone exhibited an overall RMSD fluctuation of < 2 Å for all the ligand-bound systems 
during the three simulations (except for 13 and 14). To select the promising candidate for the 
CD2-CD58 interaction inhibition, three criteria were taken into consideration: (i) a stabilized 
and low ligand RMSD for the bound conformation, (ii) a stabilized binding closer to the 
CD2-binding site (evaluated based on distance from AspA33 of CD58), and (iii) a 
comparative analysis with the initial binding conformations. For compounds 1, 3, 4, 8, 9, 10, 
12 (for Pose2 and Pose3), and 13 (for Pose2), the ligand RMSD values were lower than 3 Å 
from the initial conformation (Figure S25) with a fluctuation in the range of 1.0–1.5 Å, 
thereby indicating a stabilization of the ligand structure during the MD simulations. To 
evaluate the binding stability of the ligands at the CD2-binding site of CD58, the distance 
between the centroid of the bound ligand and AspA33 was analyzed (Figure S26). This 
distance was also compared to the initial distance between ligands and AspA33. The 
compounds which remained bound to CD58 at the CD2-binding site (distance from AspA33 
< 8 Å) during all the three simulations are 1, 4, 8, 9, and 10. Additionally, Pose2 of 
compound 3, Pose 3 of compound 12, and Pose 2 of compound 13, remained stably bound 
at the CD2-binding site of CD58 during the MD run. Although Pose3 of compound 5 shifted 
to the position overlapping with the Pose1 (with a distance from AspA33 < 10 Å), 
compound 5 was not selected as Pose1 was released from the binding site. The failure of 
Pose1 to stay in the same position reduced the confidence in this candidate. For the other 
simulations, the ligand was released from the binding site (indicated by an increased distance 
from AspA33). Based on these analyses, eight compounds, i.e., 1, 3, 4, 8, 9, 10, 12, and 13 




Figure 6. 2D structures of the eight selected molecules that exhibited stable binding to CD58 
after the MD simulations.  
The structural superimposition of the final positions of the ligands (after simulations 
of their three different starting points) for the eight compounds showed that at least two 
ligand conformations are highly overlapping for compounds 1, 4, 8, 9, and 10 (Figure S27). 
For compound 1, the ligand stayed in a rather similar position for all three simulation 
systems (Figure S27A). Surprisingly, despite starting from highly overlapping conformations 
for compounds 3, 4, 8, 9, and 10 (Figure S23), at least one of the three simulations behaved 
differently from the other two systems (Figure S27B-S27F). For compounds 12 and 13, the 
initial binding conformations were not overlapping (Figure S27G-S27H) and out of the three 
initial conformations, only one remained stably bound at the CD2-binding interface (close to 
AspA33) on CD58 for the two compounds. An additional constraint for the selection of the 
binding conformation was therefore imposed by analyzing their position on the CD2-CD58 
interface (Figure 7). As noticed in the previous sections (Figures 3 and 4), the topographical 
N-terminal ends of CD2 and CD58 have a major contribution to the CD2-CD58 complex 
formation (Figure 7A). The MD simulation replicates which showed reproducible results 
(indicated by the overlapping position of the ligands after the dynamics in Figure S27A-
S27D) were located at the topographical N-terminal end of CD58 for all selected compounds 
(Figure 7B-E), (except for compound 10), thus supporting their ability to block the 
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interactions between CD2 and CD58. For compound 10, Pose2 was located at the CD2-
binding site (Figure 7G), although Pose1 and Pose3 behaved similarly (Figure S27F). 
Considering the pharmacological significance of this binding position, the final position from 
the MD simulations for Pose2 of compound 10 was taken as the suitable binding 
conformation. After our careful analysis, the promising binding conformations proposed for 
the various compounds were Pose1 for compounds 1, 4, and 9, Pose 2 for compounds 3, 8, 
10, and 13, Pose 3 for compound 12. 
 
Figure 7. Structural superimposition of the CD2-CD58 complex (CD2 in yellow and CD58 
in grey) (A)) with the optimized complexes (after MD) of the selected ligands and CD58 for 
compound (B) 1, (C) 3, (D) 4, (E) 8, (F) 9, (G) 10, (H) 12, and (I) 13.  
The selected conformation and the ligand position obtained after MD simulations 
(Figure S28, shown in blue) were mostly in the same location as the one obtained after 
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molecular docking (Figure S28, in yellow). The residue-wise atomic fluctuation exhibited a 
similar pattern for the selected simulation system (corresponding to the most stable binding 
conformation) of the various complexes (Figure S29). The residues which exhibited the 
lowest fluctuation during the MD simulations include LysA30, AspA33, LysA34, ValA35, 
ArgA44, PheA46, SerA47, SerA48, PheA49, SerA69, SerA70, AspA71, and GluA72 (Figure 
S30). The lower fluctuation in these residues points towards their possible role in the binding 
of the selected compounds, as the complex formation results in a reduced degree of freedom 
for the residues located at the binding site. After the qualitative evaluation of the generated 
complexes and identification of the residues taking part in the complex formation, a 
quantitative evaluation of the complex formation was achieved through MM/GBSA ∆Gbind 
calculations for the eight compounds in the various ligand configurations. 
For compounds 1, 3, 4, 8, 9, and 10, at least two simulations exhibited a highly 
overlapping quantitative pattern of MM/GBSA ∆Gbind values over the period of 50 ns 
simulation (Figure S31). For compounds 12 and 13, we noted a significant difference in the 
binding energy for the three poses. The selected conformations (i.e., Pose1 for compounds 1, 
4, and 9, Pose 2 for compounds 3, 8, 10, and 13, Pose 3 for compound 12) exhibited the 
highest binding affinity amongst the three simulations for each compound. Contrary to the 
CD2-CD58 complex formation, the binding energy of the selected compounds with CD58 
was stabilized during the short period of simulation, which is attributed to the relatively 
overall smaller size of the bound ligands (as compared to CD2). Additionally, the selected 
compounds exhibited a higher degree of structural flexibility as compared to the cyclic 
peptides reported in literature,21–25 which allowed the simulation algorithm to accommodate 
selected compounds on the CD2-binding interface. The MM/GBSA ∆Gbind, values averaged 
over the last 10 ns of MD simulations, of the selected binding conformations for various 
compounds are reported in Table 2. The order of binding strength for the selected molecules 
is compounds 12 > 1 > 13 > 8 > 9 > 10 > 3 > 4. The selected eight compounds exhibit 
heterocyclic rings (except compounds 10 and 12) and a bridging amide and/or sulphonamide 
functional group connecting two ring systems. The presence of multiple amide groups (or 
sulfonamide group) contributed positively to the binding energy of the selected compounds. 
Regarding compounds 4 and 10, the carboxylate functional group is exposed to solvent, and 
the contribution from ΔGsolv is, therefore, higher (numerically lower value) as compared to 
the other five non-ionic compounds. It was interesting to note that the presence of an amide 
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functional group (absent in compound 4) increased the contribution from the electrostatic 
energy (EEL).  
The per-residue decomposition energy analysis for the various compounds helped to 
recognize the residues having a significant contribution to the complex formation (< −1 
kcal/mol) (Figure S32). The important residues include LysA30, AspA33, LysA34, ValA35, 
PheA46, SerA47, SerA48, and PheA49. From those residues, LysA34, ValA35, PheA46, 
SerA47, and PheA49 were involved in ligand binding for at least three systems (indicated by 
multi-colored stacked bars in Figure 8A). The average number of hydrogen bonds between 
CD58 and the identified hits was calculated to be 2, 1, 1, 2, 2, 3, 2, and 2 for compounds 1, 
3, 4, 8, 9, 10, 12, and 13, respectively (Figure S33). The residues which were involved in the 
formation of the complex via H-bond formation are LysA30, AspA33, LysA34, SerA47, 
SerA48, and PheA49 (Figure 8B). The side chains of the residues participating in interactions 
with the selected ligands adopted a different configuration to accommodate the ligands more 
comfortably at the CD2-interacting surface (Figure S34). The pKa values were predicted for 
CD58 by using the centroid of each cluster (based on interfacial residues, Figure S9) using 
the PDB2PQR server (http://server.poissonboltzmann.org/pdb2pqr).56 The results indicated 
that despite the change in the side change orientations in CD58, there were no significant 
differences between the predicted pKa values for the various amino acids (Figure S35). To 
evaluate the effect of the force field on the binding of ligands to CD58, we performed a 
comparative analysis for the compound 1 by applying the GAFF2,31 and FF14SB force 
field.32 Although the calculated affinity with recent force fields was weaker than that with 
GAFF29 and FF99SB,30 the pattern of MM/GBSA ∆Gbind values was comparable with the two 
force fields (Figure S36). A comparative analysis of the important residues interacting with 
the previously reported cyclic peptides24–26 and the identified hits from the current study was 
performed thereafter. For the cyclic peptides, GluA25, LysA29, AspA33, LysA34, and 
ArgA44 from CD58 are reported to participate in the complex formation.26 LysA34 was 
identified as a strong anchor point in the CD58-cyclic peptide complex.26 Interestingly, 
AspA33 and LysA34 also played a key role in the binding of the selected hits in this work, 
which increases the confidence in the inhibitory potential of the selected hits. As already 
mentioned, the reported cyclic peptide inhibitors24,25 were observed to move from the initial 
and expected site of interaction in CD58,26 which can be the reason for a lower overlap in the 
interacting residue for the identified ligands reported herein.  
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Table 2. MM/GBSA ∆Gbind values in kcal/mol calculated after the 50 ns MD simulations 
(averaged over the last 10 ns) for the selected compounds.*  
*The meaning of the different terms used in this table is as follows: VDW = van der Waals energy as calculated 
by the MM force field. EEL = electrostatic energy is calculated by the MM force field. EGB = the electrostatic 
contribution to the solvation free energy calculated by GB. ESURF = nonpolar contribution to the solvation free 
energy calculated by an empirical model. ΔGgas = total gas phase energy, i.e., the sum of the van der Waals and 
electrostatic energy from MM. ΔGsolv = total free energy of solvation, i.e., the sum of the electrostatic and 
nonpolar contributions from solvation. ΔGbind = final estimated binding free energy calculated from the terms 
above (kcal/mol). 
 
Figure 8. Identification of the interacting residues for the eight selected compounds after the 
MD simulations with the help of the (A) decomposition energy analysis and (B) the H-bond 
occupancy analysis, for which the cumulative percentage of frames exhibiting the presence of 
H-bond with each residue for all the compounds is provided.  
From the detailed analyses of MD simulations, it can thus be suggested that 
compounds 1, 3, 4, 8, 9, 10, 12, and 13 exhibited the binding characteristics (including 
binding position, binding energy, and the residues involved in the interactions) which make 
them promising hits as inhibitors of CD2 interactions with CD58. The various molecular 
properties of the selected compounds, which are known to affect the pharmacokinetics of 
small molecules, were within the acceptable range, i.e., molecular weight < 500 Da, LogP < 
5, HBA < 10, HBD < 5, TPSA < 140 Å2 (Table S9). Source libraries and commercial details 
of these compounds are provided in Table S10. The selected compounds offer the opportunity 
of developing non-peptidic inhibitors of CD2-CD58 interactions and can be evaluated 
experimentally to ascertain the findings from our work. 
Compound VDW EEL EGB ESURF ΔGgas ΔGsolv ΔGbind 
1 -36 -30 43 -5 -66 37 -28 ± 3 
3 -29 -19 34 -4 -48 31 -17 ± 3 
4 -27 47 -33 -4 20 -37 -17 ± 3 
8 -26 -26 33 -4 -52 29 -23 ± 4 
9 -26 -25 36 -3 -51 33 -18 ± 3 
10 -19 -7 11 -3 -26 8 -18 ± 4 
12 -27 -30 32 -4 -57 28 -29 ± 4 




The interaction between CD2 and CD58 is the preliminary phenomenon in the 
physiological immune response mediated via T-cells and APCs. Inhibition of CD2-CD58 
interactions is established as a suitable strategy to develop immunosuppressive agents, which 
have a wide range of therapeutic applications. With this information in hand, we performed a 
systematic virtual screening for the identification of CD58-binding agents which have the 
potential to inhibit the interaction of CD2 with CD58. In the first step, MD simulations (500 
ns, in triplicate) were performed for the CD2-CD58 complex. After ensuring the stabilization 
of the systems and reproducibility of the results, the residues which stably contributed to the 
CD2 binding by more than −1 kcal/mol were identified. These include LysA32, AspA33, 
ArgA44, and PheA46. A pharmacophore map was created with these residues by 
incorporating nine structural features, i.e., two HBA (A1 and A4), three HBD (D6, D7, and 
D9), two hydrophobic groups (H10 and H11), one negative functional group (N12), and one 
aromatic group (R15). Screening against the developed pharmacophore resulted in 5,882 
compounds out of the 227,228 molecules, which exhibited at least six out of nine features and 
were taken for the next step property-based filtering. Druglikeness and ADME evaluation 
resulted in funneling the number of selected compounds to 343 molecules.  
Molecular docking based screening was next performed using induced fit docking, and 
subsequent Prime MM/GBSA ∆Gbind calculations. From the screened set, fifteen compounds 
exhibited a binding affinity equivalent to −50 kcal/mol, which were taken for the next step, 
i.e., MD simulations (50 ns, in triplicate). A systematic analysis of the dynamics helped to 
identify eight compounds exhibiting reproducible and stable binding with CD58. The selected 
compounds 1, 3, 4, 8, 9, 10, 12, and 13, exhibited MM/GBSA ∆Gbind of −28, −17, −17, −23, 
−18, −18, −29, and −24 kcal/mol, respectively. The residues which are involved in the 
interactions with identified hits include LysA30, AspA33, LysA34, ValA35, PheA46, 
SerA47, SerA48, and PheA49 are located at the CD2-binding interface of CD58. The 
interaction of the selected hits with the topographical N-terminal end of CD58 at the CD2-
binding interface further supports their candidature as CD58-binding agents, and hence an 
experimental evaluation can be followed. Let us stress that the selected compounds have 
passed through the various applied ADMET filters. The hits identified in our work open the 
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Molecular Dynamics simulations 
The crystallographic structure of the complex CD2-CD58 is available in the 
RCSB/Protein Data Bank (PDB ID: 1QA9).1 To evaluate the dynamics of the complex and to 
identify the residues which are critical for its formation, MD simulations were performed 
using the AMBER18 package.2 Additionally, complexes between CD58 and hits obtained 
after virtual screening (discussed in subsequent sections) were also considered through MD 
simulations. The systems preparation was performed with the help of Amber tools.2 Ligands 
and proteins were handled using the General Amber Force Field (GAFF)3 and the Amber 
ff99SB force field,4 respectively. When needed, the atomic charges of the small molecules 
were derived using the AM1-bcc method (semi-empirical with bond charge correction)5 of 
the antechamber module from Amber tools.2 Explicit water molecules (using TIP3P water 
model)6 were considered for solvation of the systems (with a cubic box with an edge not 
closer than 15 Å to the protein) and counter ions were added to neutralize the overall charge 
on the generated assemblies. Additionally, a required number of Na+ and Cl- ions were 
included to maintain an ionic concentration of 0.15 M (isotonic to body fluids) (Table S1).  
Table S1. Details of the generated assemblies for MD simulations.  
Sl. 
No. 







68 64 15,710 50,490 
2 Apo-CD2 33 32 11,100 35,071 
3 Apo-CD58 23 20 8,864 28,157 
The generated assemblies were submitted to a three-step minimization, in which 
restraint weights of 3.0 and 1.0 kcal/mol/A2 were applied at the first two steps, respectively, 
on the protein and ligands, whereas solvent and ions were minimized without any restraint. 
The third step was an unrestrained minimization of the entire system. Thereafter gradual 
heating (from 0 to 300 K, under NVT ensemble) was performed. This was followed by a 
three-step density equilibration (under NPT ensemble), in which the restraint force constant 
was decreased from 2.0 to 1.0 to 0.0 kcal/mol/A2, on the protein and ligands. Finally, an 
equilibration (1 ns under NPT, at 310 K and 1 atm pressure) and production run (1000 ns 
under NPT) were performed (pressure relaxation time = 2.0 ps, time step = 2 fs, and cutoff 
distance for non-bonded interactions = 12 Å). The particle-Mesh Ewald (PME) method7 was 
employed for the treatment of long-range electrostatic interactions and the SHAKE 
algorithm8 was used to constraint all the covalent bonds involving hydrogen atoms. The bulk 
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effect was simulated by enabling periodic boundary conditions. All the simulations were run 
in triplicate to evaluate the reproducibility of the results. The result analysis was performed 
with the help of the Ptraj module9 of the Amber tools set2 and Visual Molecular Dynamics 
software (VMD).10 The replicate simulations were submitted to a combined clustering 
analysis (using the Ptraj module)9 by employing the hierarchical agglomerative (bottom-up) 
approach as the clustering algorithm (maximum number of clusters: 5) and considering the 
best-fit coordinate root mean square deviation (RMSD) between all the heavy atoms as 
clustering parameter. The calculation of the binding energy (∆Gbind) values was performed 
using the MM/GBSA method.11 
 
Figure S9. The ionizable residues in the CD58 structure and their states predicted from 
PROPKA, which were subsequently utilized for molecular docking and molecular dynamics. 
 
Figure S10. Location of the N-terminal and C-terminal residues (A) in the CD2-CD58 
complex (CD2 in cyan and CD58 in green, PDB ID: 1QA9), and (B) with respect to the 
expected ligand-binding site. 
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Table S2. Molecules considered for virtual screening along with their source libraries. 
Sl. No. Library Number of compounds 
1 ASINEX 11,377 
2 Chembridge 100,000 
3 Chemdiv 12,995 
4 Enamine 65,512 
5 LifeChemicals 22,944 
6 Maybridge 14,400 
 Total 227,228 
Table S3. QikProp properties considered for the property based virtual screening. 
Molecular Property calculated using QikProp 
Molecular weight Dipole moment (D)  
Total solvent accessible surface area (SASA) 
(Å2) 
Hydrophobic SASA (Å2) 
Hydrophilic SASA (Å2) Carbon Pi SASA (Å2) 
Weakly polar SASA molecular volume (Å3) van der Waals polar surface area 
(PSA) (Å2) 
Number of rotatable bonds Number of hydrogen bond donors 
Number of hydrogen bond acceptors Globularity (sphere = 1) 
Ionization potential (eV) Electron affinity (eV) 
QP polarizability (Å3) QP LogP (in various solvents) 
QP LogS for aqueous solubility Conformation independent QP LogS 
QP LogKhsa as a measure of serum protein 
binding 
QP LogBB for brain/blood 
Number of primary metabolites (#metabol) Predicted CNS activity (-- to ++) 
Log IC50 HERG K+ channel blockage 
(QplogHERG) 
Apparent Caco-2 permeability 
(nm/sec) (QpPcaco) 
Apparent MDCK permeability (nm/sec) QP LogKp for skin permeability 
Max transdermal transport rate (Jm) Lipinski rule of 5 violations 
Jorgensen rule of 3 violations Qualitative model for human oral 
absorption 







Results and Discussion 
Structural information 











1HNF apo-CD2 182 2.5 Å -NA- 0.193 
1CCZ apo-CD58 171 1.8 Å 0.243 0.202 
1QA9 CD2-CD58 complex 102-95 (CD2-CD58) 3.2 Å 0.281 0.223 
Table S5. List of atom pairs with close contacts in the crystal structure (PDB ID: 1QA9).1 
Chain A refers to CD58 (highlighted in green) and Chain B refers to CD2 in the dimer used 
for the molecular modeling studies. The intermolecular close contacts are highlighted in 
yellow and are shown in bold.  
Sl. No.  Atom1 Atom2 Interatomic distance (Å) Clash overlap (Å) 
1 ThrA83@H IleA82@HG12 1.02 1.13 
2 IleA82@HB SerA79@O 1.57 1.04 
3 ThrA83@N IleA82@HG12 1.74 1.01 
4 LysA34@NZ ArgB48@HH21 1.70 0.88 
5 ValB93@HB IleB85@HG22 1.56 0.87 
6 TyrA65@HA AsnA12@HB3 1.59 0.85 
7 LysA34@HZ3 ArgB48@HH21 1.24 0.83 
8 LysA34@NZ ArgB48@NH2 2.30 0.80 
9 ValB93@HB IleB85@CG2 2.11 0.80 
10 LysB96@NZ ProB22@HG2 1.97 0.79 
11 MetA86@HE1 ValA17@HG13 1.72 0.72 
12 GlyB66@O IleB21@HD11 1.89 0.71 
13 GluB52@HB3 LysB51@O 1.89 0.70 
14 GlnA31@HB2 LysA30@O 1.92 0.69 
15 AlaB67@HB3 LeuB63@HB2 1.74 0.69 
16 LysA34@HZ3 ArgB48@NH2 1.89 0.66 
17 AspA84@H IleA82@CD1 2.09 0.66 
18 AspA84@HA IleA82@HD11 1.77 0.66 
19 AsnB65@HB2 LysB64@O 1.99 0.63 
20 LysA34@HZ1 ArgB48@NH2 1.97 0.62 
21 LysA87@HG2 GluA76@HB2 1.82 0.62 
22 LysA87@O SerA2@HA 2.00 0.62 
23 LysB96@HZ2 ProB22@HG2 1.65 0.61 
24 ThrA83@N IleA82@CG1 2.51 0.60 
25 ArgB48@HE AspB32@HB2 1.66 0.60 
26 ThrA14@H ValA13@HG12 1.67 0.59 
27 IleA82@HG22 ProA80@O 2.02 0.58 
28 SerA79@HB2 ValA26@HG22 1.86 0.57 
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29 IleA82@H ProA80@C 2.05 0.57 
30 AspA84@N IleA82@CD1 2.68 0.57 
31 IleB102@O IleB102@HG13 2.04 0.57 
32 LysB69@N LeuB68@HD22 2.18 0.57 
33 IleB85@HD11 IleB33@HD13 1.85 0.57 
34 AspA84@CA IleA82@HD11 2.35 0.56 
35 ValA92@HG11 SerA69@HA 1.88 0.56 
36 LeuB100@HD23 AspB77@O 2.06 0.56 
37 AspA84@N IleA82@HD11 2.22 0.55 
38 TyrA91@HA GluA72@HG3 1.88 0.55 
39 SerA41@HB2 AsnA40@O 2.08 0.54 
40 ArgB48@HA AspB31@O 2.08 0.54 
41 LysB69@O TyrB60@HA 2.07 0.54 
42 ArgA52@H LysA50@C 2.11 0.53 
43 AspA84@H IleA82@HD13 1.75 0.52 
44 AspB99@HB3 GluB8@HA 1.92 0.52 
45 GlyA93@HA3 GlyA7@O 2.11 0.51 
46 AspB40@OD2 LysB37@HD3 2.10 0.51 
47 LeuB68@HB2 TrpB35@CE2 2.45 0.51 
48 SerA61@O LeuA55@HD12 2.12 0.50 
49 PheB47@HD2 IleB33@HG13 1.77 0.50 
50 ValB83@HG22 TrpB35@CZ3 2.45 0.50 
51 IleA82@HD11 LysB41@NZ 2.27 0.49 
52 ThrA83@HG23 IleA82@O 2.13 0.49 
53 LeuA67@HD11 ValA13@CG2 2.43 0.48 
54 AspA71@CG ArgA52@HH22 2.16 0.48 
55 AspB79@CG SerB39@HG 2.17 0.48 
56 GluB8@N AlaB6@O 2.46 0.48 
57 IleB85@HG13 IleB33@HA 1.96 0.48 
58 ProA22@HD2 GlnA21@HG2 1.97 0.47 
59 GluA39@OE2 LysB51@CD 2.62 0.47 
60 AspA84@HA LysB41@HZ2 1.78 0.47 
61 GluB52@HG2 GluB52@O 2.15 0.47 
62 TyrA10@HB2 LysA9@O 2.18 0.43 
63 LeuA27@N ValA26@CG1 2.80 0.43 
64 LysB64@C LeuB63@O 2.55 0.43 
65 LeuB68@HD21 TyrB60@HB3 2.01 0.43 
66 LysA24@HA LysA24@HD3 1.90 0.42 
67 SerA41@CB AsnA40@O 2.67 0.42 
68 SerA59@O ValA17@HB 2.19 0.42 
69 SerA61@N SerA59@O 2.53 0.42 
70 TyrA75@CZ LysA30@HG3 2.54 0.42 
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71 SerA95@O ValA8@HB 2.19 0.42 
72 AsnB65@CB LysB64@O 2.67 0.42 
73 ValB83@HG22 TrpB35@CE3 2.55 0.42 
74 ThrA14@N ValA13@HG12 2.33 0.41 
75 AsnA40@HD22 AsnA40@HA 1.60 0.41 
76 SerA59@HA SerA19@OG 2.19 0.41 
77 SerA61@OG HisA16@HA 2.20 0.41 
78 ProA80@HB3 LysB42@NZ 2.35 0.41 
79 GlyA93@CA GlyA7@O 2.68 0.41 
80 LysB41@N ThrB38@O 2.54 0.41 
81 HisB72@C LysB71@O 2.59 0.41 
82 TyrA75@CE1 LysA30@HG3 2.57 0.40 
83 ThrB59@H LysB57@C 2.25 0.40 
84 ThrB59@N LysB57@C 2.73 0.40 
85 ValB83@N LysB82@HG2 2.36 0.40 
 
Figure S11. Structural overlap between apo-CD2 (orange, PDB ID: 1HNF), apo-CD58 
(magenta, PDB ID: 1CCZ) and CD2-CD58 complex (CD2 in cyan and CD58 in green, PDB 
ID: 1QA9) to identify the residue differences. The mutated residues in the crystal structure of 




MD analysis of CD2-CD58  
 
Figure S12. Combined clustering analysis of the triplicate MD trajectories for the CD2-
CD58 complex by considering the RMSD of all heavy atoms (A) in the complex, (B) in CD2, 
and (C) in CD58.  
Table S6. All-atom root mean square deviation (RMSD) values between the centroids of 
various clusters for the combined clustering analysis of the three replicate MD simulations, 
shown in Figure S4. The RMSD value (in Å) is indicated for clustering based on all atoms in 
the complex (for CD58 based clustering/for CD2 based clustering) for each cluster pair. 
Cluster C#0 C#1 C#2 C#3 C#4 
C#0 0 1.74 (1.15/1.88) 1.78 (0.85/1.01) 1.52 (1.96/1.51) 2.19 (0.90/0.81) 
C#1  0 2.16 (1.57/1.77) 2.80 (1.76/1.15) 2.78 (1.19/1.91) 
C#2   0 1.24 (2.25/1.47) 2.77 (0.99/1.09) 
C#3    0 2.69 (1.88/1.40) 
C#4     0 
 
 




MD analysis of apo-CD2 and apo-CD58  
 






Figure S15. Comparative atomic fluctuation analysis (A), (B), and (C) between apo-CD2 
(green) and apo-CD58 (magenta) with the complex (black) from the triplicate MD 
simulations, (D) residues numbers which exhibited atomic fluctuation higher than 3 Å in the 
CD58 during the triplicate MD simulations, and (E) topographical location of the residues 




MM/GBSA ∆Gbind analysis 
 
Figure S16. MM/GBSA ∆Gbind calculation for each of the 20 ns simulation trajectory for the 
CD2-CD58 complex (A) over 500 ns, (B) from 400 ns to 500 ns. 
 
 
Figure S17. Clustering analysis of selected interfacial residues in the CD2-CD58 complex 
during Run1, Run2, and Run3, performed for each individual simulation replicate. 
 
Figure S18. Per-residue decomposition energy analysis for the selected CD58 residues over 





Figure S19. Identification of the important CD2 residues. (A) Occupancy analysis for the 
residues exhibiting decomposition energy lower than -1.00 kcal/mol for the interaction with 
CD58 during the replicate MD simulations. Per-residue decomposition energy analysis of the 
selected CD58 residues over the simulation period for (B) Run1, (C) Run2, and (D) Run3.  




Figure S20. Per-residue decomposition energy analysis for the important residues identified from the binding energy calculations on the most 




Figure S21. Combined clustering analysis of the selected interfacial residues in the CD2-
CD58 complex during the replicate MD simulations Run1, Run2, and Run3. 
Virtual screening protocol  
 
Figure S22. Virtual screening protocol followed for the identification of the CD58-binding 
inhibitors of the CD2-CD58 interactions. 
 
Figure S23. Comparative analysis between the last frame (peach) and the centroid of the 
most populated cluster (blue) (RMSD 1.43 Å). Residues important for the interfacial 
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interactions are shown as lines and those considered for the pharmacophore map development 
from the crystal structure are shown as sticks. 
 
Figure S24. Top twenty compounds (based on PhaseScreen score) screened after the 
pharmacophore-based virtual screening, overlapped with generated pharmacophore shown in 
Figure 4C. 
Properties based filtering 
The 5,882 compounds obtained after the pharmacophore-based screening were submitted to 
DruLiTo based evaluation of drug-likeness (Table S7). 3,594 compounds, with wQED larger 
than 0.4, were selected for the next screening step (Figure S14), in which additional 
pharmacokinetic parameters were evaluated using QikProp. The filtering criteria for the 
QikProp based filtering were QpLogHERG  > −5, percent absorption >75%, and #metabol < 
5. The various molecular properties, which are reported to correlate with the pharmacokinetic 
behavior of small molecules were within the recommended ranges (Figure S17-S18).  
Table S7. Number of molecules filtered after applying the various drug-likeness rules 
evaluated using DruLiTo. 
Drug likeness rule Number of molecules filtered 
BBB Rule 236 
CMC-50 like Rule 170 
Ghose Filter 1,921 
Lipinski’s Rule 3,572 
MDDR-like Rule 5,408 





All Filters 28 
 
Figure S25. Molecular property distribution of (A) molecular weight, (B) LogP, and (C) total 
polar surface area (TPSA) of the molecules with wQED > 0.4. The molecular weight 
distribution > 90% of the selected compounds was between 350 to 500 Da, whereas the LogP 
distribution range was 1 to 4, indicating a potential for membrane permeation. The total polar 
surface area for the majority of the selected molecules was below 140 Å2, supporting their 
potential to cross the membrane barrier. 
 
Figure S26. Factors correlated to the pharmacokinetic properties, i.e., (A) molecular volume, 
(B) Predicted aqueous solubility (QPLogS), and (C) Predicted apparent Caco-2 cell 
permeability (QPPCaco) for the molecules with QpLogHERG  > −5, percent absorption 
>75%, and #metabol <5, filtered after QikProp based property calculations. The number of 
compounds that exhibited the selected features in the allowed range was 343. These filtered 
compounds exhibited a molecular volume in the range of 800 to 1,800 Å3 (recommended 
range: 500–2,000 Å3), predicted aqueous solubility (QPLogS) in the range −8 to −2 mol/dm3 
(recommended range –6.5 to 0.5 mol/dm3), and predicted apparent Caco-2 cell permeability 




Figure S27. 2D structure of the compounds selected after molecular docking based virtual 
screening, which than were further submitted to MD simulations to evaluate their binding to 
CD58.  




Figure S28. Structural overlap of the top-scoring poses for the selected molecules 
(compounds 1-15). The structural components of CD58 which were not considered for 
minimization during IFD are shown as grey. 
Figure S29. 2D interactions diagram for compounds 1-8. Hydrogen bonds: magenta lines; 
π···π interactions: green lines; NH···π/ CH···π interactions: red lines; salt bridges: blue and 




Figure S30. 2D interactions diagram for compounds 9-15. Hydrogen bonds: magenta lines; 
π···π interactions: green lines; NH···π/ CH···π interactions: red lines; salt bridges: blue and 




Figure S31. Structural superimposition of top three poses for compounds 1-15, based on 
MM/GBSA ∆Gbind values, after Induced Fit Docking (IFD). CD58 is shown as cartoon 





Table S8. Prime-MM/GBSA ∆Gbind (in kcal/mol) values for the top three poses obtained after 
the Induced Fit Docking (IFD) of compounds 1-15. 
Molecule Pose1 Pose2 Pose3 
Compound 1  −65 −50 −46 
Compound 2  −60 −52 −51 
Compound 3  −59 −58 −55 
Compound 4  −58 −57 −56 
Compound 5  −56 −52 −51 
Compound 6  −59 −58 −56 
Compound 7  −53 −52 −51 
Compound 8  −54 −52 −50 
Compound 9  −54 −44 −43 
Compound 10  −51 −50 −50 
Compound 11  −57 −53 −52 
Compound 12  −51 −50 −50 
Compound 13  −50 −49 −46 
Compound 14  −53 −53 −51 





Figure S32. Analysis of the protein backbone RMSD for the MD simulations of compounds 





Figure S33. Analysis of the ligand RMSD for the MD simulations of compounds 1-15 in the 





Figure S34. Analysis of the distance between the centroid of the bound ligand and AspA33 
(residue located at the CD2 binding site) for the MD simulations of compounds 1-15 in the 
binding conformations (Pose1 in blue, Pose2 in green, and Pose3 in magenta). The initial 





Figure S35. Superimposition of the ligand position at the end of MD simulations for the eight 





Figure S36. Overlap between the docked (yellow) and stable conformation after MD 
simulations (blue) for (A) compound 1, (B) 3, (C) 4, (D) 8, (E) 9, (F) 10, (G) 12, and (H) 13. 





Figure S37. Atomic fluctuation analysis for the selected eight ligands (Pose1 in blue, Pose2 




Figure S38. CD58 residues exhibiting the lowest atomic fluctuation (< 2 Å) for the selected 




Figure S39. MM/GBSA ∆Gbind values (in kcal/mol) of the three different binding 
conformations (Pose1 in blue, Pose2 in green, and Pose3 in magenta) for the selected eight 






Figure S40. Per-residue decomposition energy analysis for the most stable binding 




Figure S41. Number of hydrogen bonds between CD58 and the most stably bound binding 
conformation of the selected compounds over the last 20 ns MD simulation.  
 
Figure S42. Comparative analysis between the initial (blue) and final (green) structure of 
CD58 in complex with ligands. The ionization state of the amino acids was maintained the 
same as that predicted using PROPKA (Figure S1). The ionizable residues which were close 





Figure S43. PROPKA analysis (http://server.poissonboltzmann.org/pdb2pqr)12 on CD58 
(centroid structure) in the various clusters after MD simulations of CD2-CD58 complex and 
complex with the ligand. For clarity, only the top two clusters (ranked by population size) is 
shown in the lower panel.  
Comparative analysis between results from GAFF/FF99SB and GAFF2/FF14SB 
 
Figure S44. Comparative analysis of the MM/GBSA ∆Gbind values calculated over the period 
of simulation for the three binding conformations (Pose 1, Pose2, and Pose 3) of compound 
1 (bottom row) by applying GAFF/FF99SB,3,4 and GAFF2/FF14SB.13,14  
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Table S9. Various molecular properties of the compounds selected after virtual screening. 
(MW = molecular weight; HBA = hydrogen bond acceptor, HBD = hydrogen bond donor, 
TPSA = total polar surface area, AMR = molar refractivity, nRB = number of rotatable 
bonds, nAtom = number of atoms, nRigidB = number of rigid bonds). 
Compound  MW LogP HBA HBD TPSA AMR nRB nAtom nRigidB 
1 406.14 0.903 10 2 115.7 106.76 5 48 29 
3 405.18 0.053 8 2 103.23 111.18 6 53 27 
4 379.15 1.181 7 1 82.44 107.28 6 49 25 
8 447.23 1.319 9 3 103.01 113.19 5 62 30 
9 383.16 1.392 6 2 71.95 109.29 7 50 24 
10 340.14 1.343 6 3 95.5 97.79 8 45 18 
12 439.21 0.444 8 3 121.98 113.95 13 63 18 
13 467.21 1.162 9 1 113.63 118.06 11 65 23 
Table S10. Source library details and CAS registry number (CAS#) for the selected 
compounds. 
Compound Source Library ID in the source 
library 
CAS# 
1  Enamine  Z70903563 919925-66-9 
3 Enamine Z512963032 1302200-63-0 
4 ChemBridge 89402576 1452580-17-4 
8 Enamine Z1310770108 1376138-02-1 
9 ChemBridge 85137294 1497566-77-4 
10 ChemBridge 9158528 940487-85-4 
12 ChemDiv K938-0746 899704-88-2 
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